SPRO vs. ARQT
SPRO (Spero Therapeutics, Inc.) and ARQT (Arcutis Biotherapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, SPRO returned -31.31%/yr vs -0.16%/yr for ARQT. At a 0.26 correlation, their price movements are largely independent.
Performance
SPRO vs. ARQT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SPRO achieves a -5.15% return, which is significantly higher than ARQT's -8.20% return.
SPRO
- 1D
- -3.07%
- 1M
- -19.93%
- YTD
- -5.15%
- 6M
- -6.75%
- 1Y
- -26.82%
- 3Y*
- 11.37%
- 5Y*
- -31.31%
- 10Y*
- —
ARQT
- 1D
- 1.72%
- 1M
- 27.80%
- YTD
- -8.20%
- 6M
- -10.84%
- 1Y
- 92.91%
- 3Y*
- 44.81%
- 5Y*
- -0.16%
- 10Y*
- —
SPRO vs. ARQT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
SPRO Spero Therapeutics, Inc. | -5.15% | 126.21% | -29.93% | -15.03% | -89.19% | -17.43% | 100.31% |
ARQT Arcutis Biotherapeutics, Inc. | -8.20% | 108.47% | 331.27% | -78.18% | -28.64% | -26.27% | 22.04% |
Correlation
The correlation between SPRO and ARQT is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Jan 31, 2020 | 0.26 |
Fundamentals
SPRO:
$126.59M
ARQT:
$3.45B
SPRO:
$0.39
ARQT:
-$0.02
SPRO:
2.31
ARQT:
8.42
SPRO:
2.39
ARQT:
18.19
SPRO:
$54.77M
ARQT:
$415.62M
SPRO:
$54.51M
ARQT:
$377.98M
SPRO:
$12.49M
ARQT:
$12.21M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SPRO vs. ARQT — Risk / Return Rank
SPRO
ARQT
SPRO vs. ARQT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SPRO | ARQT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.07 | ||
| Sortino ratioReturn per unit of downside risk | -2.70 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.30 | -0.34 |
| Calmar ratioReturn relative to maximum drawdown | -0.68 | 2.49 | -3.17 |
| Martin ratioReturn relative to average drawdown | -1.16 | 5.68 | -6.84 |
Loading charts...
Drawdowns
SPRO vs. ARQT - Drawdown Comparison
The maximum SPRO drawdown since its inception was -97.46%, roughly equal to the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for SPRO and ARQT.
Loading charts...
Drawdown Indicators
| SPRO | ARQT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.46% | -95.02% | -2.44% |
Max Drawdown (1Y)Largest decline over 1 year | -39.80% | -37.50% | -2.30% |
Max Drawdown (3Y)Largest decline over 3 years | -68.89% | -83.24% | +14.35% |
Max Drawdown (5Y)Largest decline over 5 years | -97.13% | -93.28% | -3.85% |
Current DrawdownCurrent decline from peak | -89.99% | -27.91% | -62.08% |
Average DrawdownAverage peak-to-trough decline | -62.42% | -50.01% | -12.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.07% | 16.43% | +6.64% |
Volatility
SPRO vs. ARQT - Volatility Comparison
Spero Therapeutics, Inc. (SPRO) has a higher volatility of 33.20% compared to Arcutis Biotherapeutics, Inc. (ARQT) at 10.98%. This indicates that SPRO's price experiences larger fluctuations and is considered to be riskier than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SPRO | ARQT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 33.20% | 10.98% | +22.22% |
Volatility (6M)Calculated over the trailing 6-month period | 45.15% | 37.84% | +7.31% |
Volatility (1Y)Calculated over the trailing 1-year period | 58.66% | 58.08% | +0.58% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 152.13% | 71.90% | +80.23% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 124.91% | 76.82% | +48.09% |
Dividends
SPRO vs. ARQT - Dividend Comparison
Neither SPRO nor ARQT has paid dividends to shareholders.
Financials
SPRO vs. ARQT - Financials Comparison
This section allows you to compare key financial metrics between Spero Therapeutics, Inc. and Arcutis Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SPRO and ARQT have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SPRO has higher volatility (33.20%) compared to ARQT (10.98%). In terms of maximum drawdown, SPRO dropped -97.46% vs ARQT's -95.02%.
ARQT currently has the higher Sharpe Ratio (1.61 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SPRO and ARQT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer